Morning versus afternoon immunotherapy for advanced cancer
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of these advanced or metastatic cancers: non-small cell lung cancer, head and neck cancer, kidney cancer, bile duct or gallbladder cancer, liver cancer, melanoma, or stomach/esophageal cancer.
- You must be planning to start a standard FDA-approved immunotherapy (like a PD-1 or PD-L1 inhibitor) for your cancer.
- You must not have had immunotherapy for your cancer before.
- You must not be on other drugs that suppress your immune system in the 4 weeks before your first infusion (except low-dose steroids or inhaled steroids for asthma, for example).
- You must not have uncontrolled autoimmune disease or active untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy at different times of the day (chrono-immunotherapy) is better for people with advanced melanoma. It looks at how timing might affect how well the treatment works and side effects.
This study tests additional therapies given alongside standard immunotherapy for advanced melanoma or liver cancer. The goal is to see if adding these treatments can make the immunotherapy work better.
This trial compares giving the same combination of two immunotherapy drugs in the morning versus the afternoon. It aims to see if timing affects how well the treatment works and how long people live.
This trial tests whether the time of day you receive immunotherapy (in the morning vs. later) affects how well it works. It is for people with advanced lung cancer or other solid tumors who are just starting or continuing PD-1/PD-L1 inhibitor treatment.
This study compares giving pembrolizumab (an immunotherapy drug) in the morning versus at a random time during the day, to see if timing affects how well it works or side effects. If you're eligible, you'll receive standard pembrolizumab treatment, but your infusion time will be assigned by the study.
This trial tests whether giving immunotherapy at a specific time of day can improve its effectiveness for advanced melanoma that cannot be removed by surgery. It may help you if you have stage IV melanoma and have not had immunotherapy in the last year.
Hear when a new Advanced Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.